AU2001235896A1 - Sodium-hydrogen exchanger type 1 inhibitor (nhe-1) - Google Patents

Sodium-hydrogen exchanger type 1 inhibitor (nhe-1)

Info

Publication number
AU2001235896A1
AU2001235896A1 AU2001235896A AU3589601A AU2001235896A1 AU 2001235896 A1 AU2001235896 A1 AU 2001235896A1 AU 2001235896 A AU2001235896 A AU 2001235896A AU 3589601 A AU3589601 A AU 3589601A AU 2001235896 A1 AU2001235896 A1 AU 2001235896A1
Authority
AU
Australia
Prior art keywords
compound
tissue
prodrug
recited
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001235896A
Other languages
English (en)
Inventor
Weichao George Chen
Eric David Cox
Angel Guzman-Perez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of AU2001235896A1 publication Critical patent/AU2001235896A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Treatment Of Water By Ion Exchange (AREA)
  • Preventing Corrosion Or Incrustation Of Metals (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2001235896A 2000-04-28 2001-02-28 Sodium-hydrogen exchanger type 1 inhibitor (nhe-1) Abandoned AU2001235896A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20043200P 2000-04-28 2000-04-28
US60200432 2000-04-28
PCT/IB2001/000277 WO2001083470A1 (en) 2000-04-28 2001-02-28 Sodium-hydrogen exchanger type 1 inhibitor (nhe-1)

Publications (1)

Publication Number Publication Date
AU2001235896A1 true AU2001235896A1 (en) 2001-11-12

Family

ID=22741697

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001235896A Abandoned AU2001235896A1 (en) 2000-04-28 2001-02-28 Sodium-hydrogen exchanger type 1 inhibitor (nhe-1)

Country Status (40)

Country Link
EP (1) EP1276737A1 (es)
JP (1) JP2003531900A (es)
KR (1) KR20020093079A (es)
CN (1) CN1225466C (es)
AP (1) AP2002002651A0 (es)
AR (1) AR028375A1 (es)
AU (1) AU2001235896A1 (es)
BG (1) BG107139A (es)
BR (1) BR0110268A (es)
CA (1) CA2407535A1 (es)
CO (1) CO5221125A1 (es)
CR (1) CR6797A (es)
CZ (1) CZ20023408A3 (es)
DZ (1) DZ3310A1 (es)
EA (1) EA004882B1 (es)
EE (1) EE200200615A (es)
GT (1) GT200100064A (es)
HN (1) HN2001000042A (es)
HR (1) HRP20020851A2 (es)
HU (1) HUP0300651A2 (es)
IL (1) IL152075A0 (es)
IS (2) IS6567A (es)
MA (1) MA26897A1 (es)
MX (1) MXPA02010600A (es)
MY (1) MY133842A (es)
NO (1) NO20025132L (es)
NZ (1) NZ521348A (es)
OA (1) OA12256A (es)
PA (1) PA8513301A1 (es)
PE (1) PE20011270A1 (es)
PL (1) PL357765A1 (es)
SK (1) SK14872002A3 (es)
SV (1) SV2002000418A (es)
TN (1) TNSN01065A1 (es)
TR (1) TR200202439T2 (es)
UA (1) UA73348C2 (es)
UY (1) UY26680A1 (es)
WO (1) WO2001083470A1 (es)
YU (1) YU79602A (es)
ZA (1) ZA200208605B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1355899A1 (en) * 2001-01-31 2003-10-29 Pfizer Products Inc. Ethanolates of sodium-hydrogen exchanger type-1 inhibitor
WO2003051845A1 (en) * 2001-12-19 2003-06-26 Pfizer Products Inc. Methods for preparing sodium-hydrogen exchanger type-1 inhibitors
MXPA04008646A (es) * 2002-05-02 2004-12-06 Pfizer Prod Inc Tratamiento para la diabetes y complicaciones diabeticas con inhibidores del nhe-1.
FR2840302B1 (fr) * 2002-06-03 2004-07-16 Aventis Pharma Sa Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
ES2220185B1 (es) * 2002-07-16 2006-04-01 Consejo Sup. De Investig. Cientificas Nuevo peptido inhibidor del intercambiador na+/h+ (pinhe), y sus aplicaciones.
CA2515939A1 (en) * 2003-02-14 2004-09-02 Smithkline Beecham Corporation Novel compounds
RU2518741C1 (ru) * 2013-03-22 2014-06-10 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "ЮЖНЫЙ ФЕДЕРАЛЬНЫЙ УНИВЕРСИТЕТ" СРЕДСТВО, ИНГИБИРУЮЩЕЕ Na+/H+-ОБМЕН, И ГАЛОГЕНИДЫ 1-ДИАЛКИЛАМИНОЭТИЛ-3-[ЗАМЕЩЕННЫЙ(ДИЗАМЕЩЕННЫЙ) ФЕНАЦИЛ]-2-АМИНОБЕНЗИМИДАЗОЛИЯ

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1056729B1 (en) * 1998-02-27 2004-12-29 Pfizer Products Inc. N-[(substituted five-membered di- or triaza diunsaturated ring)carbonyl]guanidine derivatives for the treatment of ischemia

Also Published As

Publication number Publication date
EE200200615A (et) 2004-04-15
EP1276737A1 (en) 2003-01-22
TR200202439T2 (tr) 2003-02-21
GT200100064A (es) 2002-03-22
CZ20023408A3 (cs) 2004-01-14
NO20025132L (no) 2002-12-12
DZ3310A1 (fr) 2001-11-07
KR20020093079A (ko) 2002-12-12
UA73348C2 (en) 2005-07-15
YU79602A (en) 2006-05-25
HN2001000042A (es) 2001-07-09
PL357765A1 (en) 2004-07-26
SV2002000418A (es) 2002-07-03
HRP20020851A2 (en) 2005-02-28
AP2002002651A0 (en) 2002-12-31
CA2407535A1 (en) 2001-11-08
BR0110268A (pt) 2003-12-30
CR6797A (es) 2004-05-17
IS6588A (is) 2002-10-21
UY26680A1 (es) 2001-12-28
CN1426404A (zh) 2003-06-25
CO5221125A1 (es) 2002-11-28
EA200201023A1 (ru) 2003-02-27
NZ521348A (en) 2004-09-24
CN1225466C (zh) 2005-11-02
HUP0300651A2 (hu) 2003-07-28
IL152075A0 (en) 2003-05-29
MA26897A1 (fr) 2004-12-20
TNSN01065A1 (fr) 2005-11-10
BG107139A (bg) 2003-07-31
OA12256A (en) 2003-11-06
PA8513301A1 (es) 2003-09-05
IS6567A (is) 2002-09-24
ZA200208605B (en) 2003-10-24
NO20025132D0 (no) 2002-10-25
WO2001083470A1 (en) 2001-11-08
PE20011270A1 (es) 2001-12-12
AR028375A1 (es) 2003-05-07
MXPA02010600A (es) 2003-03-10
MY133842A (en) 2007-11-30
EA004882B1 (ru) 2004-08-26
JP2003531900A (ja) 2003-10-28
SK14872002A3 (sk) 2004-03-02

Similar Documents

Publication Publication Date Title
US6492401B1 (en) N-[(substituted five-membered di- or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia
CA2303594C (en) Compounds for treating and preventing diabetic complications
AU2001235896A1 (en) Sodium-hydrogen exchanger type 1 inhibitor (nhe-1)
US6852733B2 (en) Sodium-hydrogen exchanger type 1 inhibitor
KR100464526B1 (ko) 나트륨-수소 교환체 타입 1 억제제 결정
TWI221152B (en) Method for preparing sodium-hydrogen exchanger type 1 inhibitor
JPH1087658A (ja) 新規2,4−ジオキソピロリジンおよび2,4−ジオキソテトラヒドロフラン誘導体及び該化合物を有効成分とする医薬
AU2005201428A1 (en) Method for preparing sodium-hydrogen exchanger type 1 inhibitor